When was C₂N Diagnostics founded?

C₂N Diagnostics was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is C₂N Diagnostics located?

C₂N Diagnostics is headquartered in St. Louis, United States.

How many employees does C₂N Diagnostics have?

As of Jul 17, 2025, the latest employee count at C₂N Diagnostics is 51 - 200.

Is C₂N Diagnostics a funded company?

C₂N Diagnostics is a funded company, having raised a total of $35M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 22, 2009.

When was the latest funding round of C₂N Diagnostics?

C₂N Diagnostics' latest funding was a $***** Conventional Debt round on May 12, 2025, with participation from 0 investor.

Where does C₂N Diagnostics rank among its competitors?

C₂N Diagnostics ranks 2nd amongst 41 active competitors, of which 16 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was C₂N Diagnostics, which secured $10M in May, 2025.

Who are the top competitors of C₂N Diagnostics?

C₂N Diagnostics' top competitors include ADmit Therapeutics, Todos Medical and DiamiR. Among them, C₂N Diagnostics secured the most recent funding round in May, 2025.

C₂N Diagnostics - 2026 Company Profile, Team, Funding & Competitors

C₂N Diagnostics is a series B company based in St. Louis (United States), founded in 2007 by Ilana Fogelman. It operates as a Developer of diagnostics and therapies for Alzheimer's disease. C₂N Diagnostics has raised $35M in funding from Eisai. The company has 41 active competitors, including 16 funded and 2 that have exited. Its top competitors include companies like ADmit Therapeutics, Todos Medical and DiamiR.

Company Details

Developer of diagnostics and therapies for Alzheimer's disease. The product include PrecivityAD blood test that is intended for use in patients with cognitive impairment and to determine the presence or absence of amyloid plaques in the brain. It also offers bioanalytical services for pharmaceutical and biotechnology companies.

Website: c2n.com
Social
Email ID: *****@c2ndiagnostics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2007

Location

St. Louis, United States

Stage

Series B

Total Funding

$35M in 13 rounds

Latest Funding Round

Conventional Debt, May 12, 2025, $*****

Investors

Eisai & 7 more

Ranked

2^nd among 41 active competitors

Employee Count

51 - 200 as on Jul 17, 2025

Similar Companies

ADmit Therapeutics & 54 more

View C₂N Diagnostics' full profile

C₂N Diagnostics has raised a total funding of $35M over 13 rounds. Its first funding round was on Sep 22, 2009. C₂N Diagnostics has 8 institutional investors.

Here is the list of recent funding rounds of C₂N Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 12, 2025	2659591	Conventional Debt	8431988	7043019	8973904	7803904
Mar 13, 2025	6283164	Series B	6533196	7548845	3174681	Samsung Venture Investment & 3 more
Oct 01, 2024	4446021	Grant (prize money)	9685562	7005495	2338986	GHR FOUNDATION

Access funding benchmarks and valuations. Sign up today!

View details of C₂N Diagnostics's funding rounds and investors

The founders of C₂N Diagnostics is Ilana Fogelman.

Here are the details of C₂N Diagnostics' key team members:

Ilana Fogelman: Co-Founder of C₂N Diagnostics.
Contact Info: 1 email address

View details of C₂N Diagnostics's Founder profiles and Board Members

C₂N Diagnostics' employee count trend

C₂N Diagnostics has 51 - 200 employees as of Jul 25. Here is C₂N Diagnostics's employee count trend over the years:

Employee count trend for C₂N Diagnostics

Uncover C₂N Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of C₂N Diagnostics include ADmit Therapeutics, Todos Medical and DiamiR. Here is the list of Top 10 competitors of C₂N Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ADmit Therapeutics 2017, Barcelona (Spain), Series A	Provider of diagnostic services for early detection of Alzheimer's disease	$12.9M	Ship2B, Clave & 13 others	57/100
2nd	C₂N Diagnostics 2007, St. Louis (United States), Series B	Developer of diagnostics and therapies for Alzheimer's disease	$35M	Samsung Venture Investment, Samsung BioLogics ... & 6 others	56/100
3rd	Todos Medical 2009, Rehovot (Israel), Public	Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders	-	Lincoln Park Capital, Yozma & 2 others	48/100
4th	DiamiR 2009, Monmouth Junction (United States), Funding Raised	Developer of minimally invasive diagnostic tests	-	NIA, HHS	47/100
5th	Veravas 2017, Oakdale (United States), Series A	Provider of platform to manage sample preparation and diagnostic solutions	$25M	SeedFunders	46/100
6th	ALZpath 2020, Carlsbad (United States), Seed	Developer of diagnostic solutions for Alzheimer's Disease	-	Alzheimer's Drug Discovery	42/100
7th	Amydis Diagnostics 2013, San Diego (United States), Series A	Developer of diagnostics test for detection of Alzheimer's disease	$8.69M	NIH, JLABS & 3 others	40/100
8th	SYNAPS Dx 2016, Rockville (United States), Series A	Developer of a diagnostic test to detect Alzheimer's disease	$10M	Semler Scientific	35/100
9th	NeuroDex 2018, Natick (United States), Seed	Manufacturer of diagnostic tools for Alzheimer's disease	$1.36M	ICV, HHS	34/100
10th	Vivid Genomics 2018, San Diego (United States), Seed	Developer of diagnostic tests for neurodegenerative diseases	$20K	Ad Astra Ventures, Crescent Ridge & 2 others	34/100